Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 16/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17925409 | 0.94 | FGFR1 (0.52) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL15413205 | 0.86 | FGFR1 (0.68) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL19499689 | 0.85 | FGFR1 (0.51) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL17925404 | 0.84 | FGFR1 (0.47) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL19499703 | 0.84 | FGFR1 (0.49) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL19499697 | 0.83 | FGFR1 (0.48) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL19470189 | 0.83 | FGFR1 (0.55) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL19499688 | 0.80 | FGFR1 (0.49) | FGFR1FGFR4FGFR2 | |
| SCHEMBL19499706 | 0.80 | FGFR1 (0.56) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL19499699 | 0.79 | FGFR1 (0.48) | FGFR1FGFR4FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253029-B2 | Dual-warhead covalent inhibitors of FGFR-4 | NEWAVE PHARMACEUTICAL INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | FGFR4, FGFR2, FGFR3 | FGFR1 4/4885FGFR4 1/4885FGFR2 2/4885 |
| US-10253029-B2 | Dual-warhead covalent inhibitors of FGFR-4 | FGFR4, FGFR2, FGFR3 | FGFR1 4/4885FGFR4 1/4885FGFR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.